Palatin Technologies Shares Are Trading Lower After the Company Announced Results for Its PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients With Dry Eye Disease Did Not Meet Co-primary Sign Endpoints and Secondary Sign Endpoints
Palatin Technologies公佈了針對乾眼病患者的 PL9643 MELODY-1 關鍵三期臨床試驗結果未達到共同主要體徵終點和次要體徵終點的結果後,該公司股價走低